Product Images Tri-legest Fe 28 Day

Tri-Legest Fe is a medication containing norethindrone acetate and ethinyl estradiol tablets, USP and ferrous fumarate tablets, used for contraception. The medication comes in 5 tablet dispensers with a total of 28 tablets in each dispenser. The dosage is recommended to be one tablet daily for 28 days as directed by the physician. The medication should be stored at a controlled room temperature between 20°C to 25°C (68°F to 77°F) and protected from light by storing the tablets in the wallet when not in use. The packaging box contains 5 foil pouches, each containing one informational piece, for the patient. The medication is manufactured by Teva Pharmaceuticals USA, Inc. in North Wales, PA.*

Tri-Legest Fe is an oral contraceptive that prevents pregnancy with a combination of norethindrone acetate and ethinyl estradiol tablets and ferrous fumarate tablets. The product comes in packages of 5 tablet dispensers, each containing 28 tablets of different colors based on their hormone composition. The light pink tablet contains 1 mg of norethindrone acetate and 20 mg of ethinyl estradiol while the light yellow tablet contains 1 mg of norethindrone acetate and 30 mg of ethinyl estradiol. The light blue tablet contains 1 mg of norethindrone acetate and 35 mg of ethinyl estradiol. One brown tablet contains 75 mg of ferrous fumarate. This medication does not protect against HIV infection (AIDS) or other sexually transmitted diseases. Lot/Exp information is available on the non-varnish area of the packaging.*

This appears to be a table displaying the results of a study for a treatment using Norethindrone acetate and ethinyl estradiol tablets. The table shows the mean total lesion counts for a population treated with the tablets, as well as those receiving a placebo. There are 206 participants who have been treated with the tablets and 205 receiving a placebo. The readings show that the tablet group had consistently lower lesion counts across the trial compared to the placebo group.*

This appears to be a list of different studies conducted between 2002 and 2017 that evaluated the effects of women's contraceptive use, both ever use and current use, on health outcomes. The text includes names of different studies, and some numerical values that may represent effect estimates. However, the text is not entirely clear and may require further analysis.*